1-3 of 3
Susanne Danhauser-Riedl
Close
Sort by
Journal Articles

NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)

Eugen Tausch, MD, Philipp Beck, Richard F. Schlenk, MD, Sabrina Kless, Christina Galler, Peter Hillmen, MB ChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Susanne Danhauser-Riedl, MD, Astrid McKeown, PhD, Paul D P´B Winter, PhD, Ira V Gupta, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 527.
https://doi.org/10.1182/blood.V122.21.527.527
Published: 2013
Journal Articles

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate

Christine Schuster, Karin Forster, Henning Dierks, Annika Elsässer, Gerhard Behre, Nicola Simon, Susanne Danhauser-Riedl, Michael Hallek, Markus Warmuth
Journal: Blood
Blood (2003) 101 (2): 655–663.
https://doi.org/10.1182/blood-2002-01-0043
Published: 2003
Journal Articles

Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors

Clemens-Martin Wendtner, David M. Kofler, Hans D. Theiss, Christian Kurzeder, Raymund Buhmann, Carmen Schweighofer, Luca Perabo, Susanne Danhauser-Riedl, Jens Baumert, Wolfgang Hiddemann, Michael Hallek, Hildegard Büning
Journal: Blood
Blood (2002) 100 (5): 1655–1661.
https://doi.org/10.1182/blood.V100.5.1655.h81702001655_1655_1661
Published: 2002